Recent Updates
Recently added Catalysts

Stavudine

Phase 3

AIDS Dementia Complex | Small molecule | Infectious Disease |Bristol-Myers Squibb Company|Last Updated: May 4, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

Clinical trial landscape

Stavudine · 1 trial · 2 indications

Phase 3 1
NCT00002246A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia ComplexAIDS Dementia Complex
COMPLETED20 Analytics
PHASE3COMPLETED
A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex
AIDS Dementia ComplexUnlock trial analytics

Study Design & Arms

PurposeTREATMENT

Interventions

NameTypeDescription
StavudineDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range13 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Are at least 13 years old (need consent if under 18). * Have AIDS Dementia Complex. * Have been on a stable anti-HIV drug regimen for at least 8 weeks prior to study entry. * Agree to use effective methods of birth...

Countries:United StatesAustraliaUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about Stavudine

What is Stavudine used for?

Stavudine is an investigational small molecule being studied for the treatment of HIV Infections and AIDS Dementia Complex. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 3 clinical development. Stavudine is not approved and remains under investigation for these indications.

What does Stavudine target?

Stavudine is a small molecule being studied for HIV Infections and AIDS Dementia Complex. Its molecular target has not been disclosed in the available information, so its specific mechanism of action is not described here. The drug is in Phase 3 clinical trials for these infectious disease indications.

Who makes Stavudine?

Stavudine is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting Phase 3 clinical trials for Stavudine in HIV Infections and AIDS Dementia Complex. Stavudine is an investigational small molecule and has not been approved for these uses.

What phase is Stavudine in?

Stavudine is in Phase 3 clinical development. It is being studied for HIV Infections and AIDS Dementia Complex, with two completed Phase 3 trials. Stavudine is investigational and not yet approved, as it remains in clinical trials for these indications.

What clinical trials is Stavudine in?

Stavudine has two completed Phase 3 trials: NCT00002246, which evaluated stavudine (d4T) for AIDS Dementia Complex with 20 participants in the US, Australia, and UK, and NCT00116298, a rollover study for Zerit (stavudine) ER with 900 participants across multiple countries. Both trials are completed.

Is Stavudine the same as Zerit?

Stavudine is also known as Zerit, as referenced in the clinical trial NCT00116298, which is titled 'Rollover Study for Zerit (Stavudine) ER Studies'. This indicates that Zerit is a brand name for stavudine. Stavudine is being developed by Bristol-Myers Squibb Company for HIV Infections and AIDS Dementia Complex.